Blooom Inc’s Clovis Oncology, Inc. CLVS Stock Holding History

Blooom Inc’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$18K	–	45
2022 Q2	$18K	Buy	+10,000	New	+$14.8K	0.03%	45

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Blooom Inc's CLVS Position: Q3 2022 in Review

Blooom Inc sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 10,000 shares — an estimated $18K sold.

Blooom Inc first reported a position in CLVS in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

Blooom Inc reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
Blooom Inc sold 10,000 Clovis Oncology, Inc. shares in Q3 2022, an estimated $18K.
Blooom Inc first reported a position in Clovis Oncology, Inc. in Q2 2022 and held it in 1 quarter.
Blooom Inc's Clovis Oncology, Inc. position peaked at $18K in Q2 2022.
103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Blooom Inc's 13F filing for Q3 2022, filed 1 Nov 2022.